Head-To-Head Survey: CervoMed (NASDAQ:CRVO) vs. Sensei Biotherapeutics (NASDAQ:SNSE)

CervoMed (NASDAQ:CRVO) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for CervoMed and Sensei Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1	1	5	2	2.89
Sensei Biotherapeutics	0	0	4	0	3.00

CervoMed presently has a consensus target price of $27.50, suggesting a potential upside of 223.91%. Sensei Biotherapeutics has a consensus target price of $4.25, suggesting a potential upside of 1,049.58%. Given Sensei Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than CervoMed.

Insider & Institutional Ownership

25.1% of CervoMed shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 36.3% of CervoMed shares are owned by company insiders. Comparatively, 22.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

CervoMed has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Valuation and Earnings

This table compares CervoMed and Sensei Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$7.14 million	10.35	-$2.17 million	($2.03)	-4.18
Sensei Biotherapeutics	N/A	N/A	-$34.10 million	($1.20)	-0.31

CervoMed has higher revenue and earnings than Sensei Biotherapeutics. CervoMed is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CervoMed and Sensei Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CervoMed	-118.68%	-44.11%	-39.81%
Sensei Biotherapeutics	N/A	-53.86%	-46.91%

Summary

CervoMed beats Sensei Biotherapeutics on 8 of the 13 factors compared between the two stocks.

About CervoMed

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.